Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer

Journal of Pharmaceutical Sciences

Volumn 100, Issue 10, 2011, Pages 4205-4209

  Gréen, Henrik ^a,b   Khan, Muhammad Suleman ^a   Jakobsen Falk, Ingrid ^a   Åvall Lundqvist, Elisabeth ^c   Peterson, Curt ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer chemotherapy; CYP enzymes; Drug metabolizing enzymes; Pharmacogenetics; Polymorphism; Toxicity

Indexed keywords

CARBOPLATIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A5; PACLITAXEL; ANTINEOPLASTIC AGENT; CYP2C8 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; UNSPECIFIC MONOOXYGENASE;

ALLELE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; OVARY CANCER; PHARMACOKINETICS; PROSPECTIVE STUDY; PYROSEQUENCING; SENSORY NEUROPATHY; BLOOD; CHEMICALLY INDUCED; GENETIC VARIABILITY; GENETICS; METABOLISM; OVARIAN NEOPLASMS; PHARMACOGENETICS; PHENOTYPE; RISK FACTOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARYL HYDROCARBON HYDROXYLASES; CARBOPLATIN; CYTOCHROME P-450 CYP2C8; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; LEUKOCYTE COUNT; LEUKOPENIA; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; PHARMACOGENETICS; PHENOTYPE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 80052240853     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22680     Document Type: Article

References (14)

1. Vaclavikova R, Soucek P, Svobodova L, Anzenbacher P, Simek P, Guengerich FP, Gut I. 2004. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Dispos 32:666-674.
2. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. 1994. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546.
3. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM. 1994. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026-4035.
4. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M. 1994. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54:386-392.
5. Walle T, Walle UK, Kumar GN, Bhalla KN. 1995. Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 23:506-512.
6. Green H, Soderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, Peterson C. 2009. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 104:130-137.
7. Bergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F, Skougaard K, Wihl J, Keldsen N, Damkier P, Friberg LE, Peterson C, Vach W, Karlsson MO, Brosen K. 2011. Impact of CYP2C8*3 on paclitaxel clearance: A population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 11:113-120.
8. Leskela S, Jara C, Leandro-Garcia LJ, Martinez A, Garcia-Donas J, Hernando S, Hurtado A, Vicario JC, Montero-Conde C, Landa I, Lopez-Jimenez E, Cascon A, Milne RL, Robledo M, Rodriguez-Antona C. 2011. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 11:121-129.
9. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. 2007. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer. J Clin Oncol 25:4528-4535.
10. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Vigano L, Locatelli A, Verweij J, Sparreboom A, McLeod HL. 2005. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11:8097-8104.
11. Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, Kaye SB. 1998. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol 41:161-166.
12. Rodriguez-Antona C, Niemi M, Backman JT, Kajosaari LI, Neuvonen PJ, Robledo M, Ingelman-Sundberg M. 2008. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J 8:268-277.
13. Sparreboom A, Huizing MT, Boesen JJ, Nooijen WJ, van Tellingen O, Beijnen JH. 1995. Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemother Pharmacol 36:299-304.
14. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. 2001. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.